Clinical Trial: Phase III Study of OT202 in Treating Moderate to Severe Dry Eye

U.S., Aug. 1 -- ClinicalTrials.gov registry received information related to the study (NCT07740564) titled 'Phase III Study of OT202 in Treating Moderate to Severe Dry Eye' on July 23.

Brief Summary: This is a multicenter, randomized, double-blind, placebo-controlled Phase III clinical trial, enrolling 842 subjects with moderate to severe dry eye, who will be randomized at a 1:1 ratio to receive either 1% OT202 ophthalmic solution or vehicle control. The trial consists of screening, run-in, 8-week double-blind treatment period, and three long-term safety follow-up cohorts (10 weeks, 28 weeks, and 54 weeks), including 342 subjects for the 10-week follow-up, 350 subjects for the 28-week follow-up, and 150 subjects for the 54-week follow-up. ...